M3 Europe Ltd

On 12th March 2012, M3 became part of SEC Pharma, one of Europe's leading specialist recruitment businesses for the Pharmaceutical, Clinical and Healthcare sectors.

Related News

BUSINESS INSIGHTS

GOODRX CLOSES ACQUISITION OF VITACARE, A TECH-ENABLED PHARMACY SERVICES PLATFORM

GoodRx | April 18, 2022

news image

GoodRx, a leading consumer-focused digital healthcare platform announced the completion of its previously announced acquisition of vitaCare for $150 million in cash, with an additional $7 million of consideration contingent payment upon vitaCare’s financial performance through 2023. VitaCare is a pharmacy services platform that expands GoodRx’s offering to pharmaceutical manufacturers while helping to improve patient access and adherence to affordable brand drugs. The acquisition wil...

Read More

BUSINESS INSIGHTS

DERMALIQ THERAPEUTICS SIGNS USD 15 MILLION SERIES A ROUND TO ADVANCE THREE TRANSFORMATIVE DRUG THERAPIES INTO CLINICAL TRIALS

Dermaliq Therapeutics | January 18, 2022

news image

Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd. today announced the establishment of Dermaliq Therapeutics, Inc (Dermaliq), a newly formed Delaware-based pharmaceutical development company, and the signing of a USD 15 million Series A financing round. 3E Bioventures Capital, a leading international life science investor, led the round and was joined by Beijing Whale Technology Corporation Ltd. Dermaliq's existing shareholder Novaliq has transferred, and lic...

Read More

PHARMACY MARKET

MEDIPHARM LABS ENTERS UNITED STATES PHARMACEUTICAL MARKET WITH SUBMISSION OF FDA DMF

MediPharm Labs Corp. | February 24, 2022

news image

MediPharm Labs Corp. a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has completed a US FDA DMF for pure natural CBD API. The DMF will enable MediPharm to supply approved API to pharmaceutical companies currently conducting late-stage research. The cannabis-based drug opportunity is predicted to be over USD$25 billion by 2025, and there are over 20 strong novel cannabinoid-based drugs currently in the late-stage research process. These projects wil...

Read More

RESEARCH

DARWINHEALTH ANNOUNCES SCIENTIFIC COLLABORATION WITH PRELUDE THERAPEUTICS IN ONCOLOGY

Prelude Therapeutics | October 13, 2021

news image

DarwinHealth, Inc. today announced a scientific research collaboration that uses its Biomarker Enrichment Strategies for Assays (BEST platform ) to elucidate novel biomarkers that guide translational trajectories of multiple cancer molecules being developed by Prelude Therapeutics. Under the collaboration, DarwinHealth will use its proprietary, quantitative, systems biology-based algorithms, CLIA-approved technologies, and validated approaches focused on Protein Master Regulator (...

Read More
news image

BUSINESS INSIGHTS

GOODRX CLOSES ACQUISITION OF VITACARE, A TECH-ENABLED PHARMACY SERVICES PLATFORM

GoodRx | April 18, 2022

GoodRx, a leading consumer-focused digital healthcare platform announced the completion of its previously announced acquisition of vitaCare for $150 million in cash, with an additional $7 million of consideration contingent payment upon vitaCare’s financial performance through 2023. VitaCare is a pharmacy services platform that expands GoodRx’s offering to pharmaceutical manufacturers while helping to improve patient access and adherence to affordable brand drugs. The acquisition wil...

Read More
news image

BUSINESS INSIGHTS

DERMALIQ THERAPEUTICS SIGNS USD 15 MILLION SERIES A ROUND TO ADVANCE THREE TRANSFORMATIVE DRUG THERAPIES INTO CLINICAL TRIALS

Dermaliq Therapeutics | January 18, 2022

Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd. today announced the establishment of Dermaliq Therapeutics, Inc (Dermaliq), a newly formed Delaware-based pharmaceutical development company, and the signing of a USD 15 million Series A financing round. 3E Bioventures Capital, a leading international life science investor, led the round and was joined by Beijing Whale Technology Corporation Ltd. Dermaliq's existing shareholder Novaliq has transferred, and lic...

Read More
news image

PHARMACY MARKET

MEDIPHARM LABS ENTERS UNITED STATES PHARMACEUTICAL MARKET WITH SUBMISSION OF FDA DMF

MediPharm Labs Corp. | February 24, 2022

MediPharm Labs Corp. a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has completed a US FDA DMF for pure natural CBD API. The DMF will enable MediPharm to supply approved API to pharmaceutical companies currently conducting late-stage research. The cannabis-based drug opportunity is predicted to be over USD$25 billion by 2025, and there are over 20 strong novel cannabinoid-based drugs currently in the late-stage research process. These projects wil...

Read More
news image

RESEARCH

DARWINHEALTH ANNOUNCES SCIENTIFIC COLLABORATION WITH PRELUDE THERAPEUTICS IN ONCOLOGY

Prelude Therapeutics | October 13, 2021

DarwinHealth, Inc. today announced a scientific research collaboration that uses its Biomarker Enrichment Strategies for Assays (BEST platform ) to elucidate novel biomarkers that guide translational trajectories of multiple cancer molecules being developed by Prelude Therapeutics. Under the collaboration, DarwinHealth will use its proprietary, quantitative, systems biology-based algorithms, CLIA-approved technologies, and validated approaches focused on Protein Master Regulator (...

Read More